UPMC makes $100M investment into a data warehouse

Luke Gale | | Health Exec | Digital Transformation
University of Pittsburgh Medical Center (UPMC) is investing $100 million over five years into a data warehouse with multiple analytics applications, along with partners Oracle, IBM, Informatica and dbMotion.

UPMC is engaging in a two-year project to install the hardware and software necessary to integrate data from more than 200 data sources across UPMC, including pharmacies, laboratories and the UPMC health plan, according to an Oct. 1 statement.

The university already stores more than 3.2 petabytes of information and a data warehouse will allow for multidisciplinary informatics research, with applications for administrative, clinical and accounting departments. 

Luke Gale

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.